Professor Meg Jardine is the Director of the CTC and Lead of Kidney Health Research. Her research has focussed on investigating the progression and complications of kidney disease and diabetes, through randomised trials and epidemiological analyses. Her interests include the integration of clinical care and research endeavours, and the promotion of learning health system principles to contribute to effective delivery of care. She has experience in the design and conduct of national and international trials and is particularly interested in response-adaptive techniques as a solution to many of the challenges facing trials in kidney disease. She has expertise in trials Prof Jardine is an Executive Committee member of the International Society of Nephrology and the international nephrology guidelines body, KDIGO. She contributes to policy setting and implementation through roles such as Board Member of the Kidney Health Initiative, a public-private collaboration of the American Society of Nephrology and the US FDA. Her advocacy for the kidney disease trial endeavour is pursued through roles in the AKTN, the International Society of Nephrology Advancing Clinical Trials (ISN-ACTS) core committee and the ANZSN Research Advisory Committee. She is a specialist nephrologist at Concord Repatriation General Hospital. Prof Jardine was honoured with the T.J.Neale award for Outstanding Contribution to Nephrological Science in 2020.